While treatment of hypothyroidism with daily oral levothyroxine (L-T4) alone is effective in most hypothyroid patients, about 15 percent report feeling inadequately treated and are often prescribed a combination of L-T3 with L-T4.

We are encouraged by these initial, non-clinical data demonstrating the successful delivery of L-T3 with our ProNeura continuous, long-term drug delivery platform," said Titan Executive Vice President and Chief Development Officer Kate Beebe, PhD.

In these studies, ProNeura-based L-T3 implants were formulated and tested for release characteristics in several non-clinical models.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.